Efeito de reguladores de crescimento sobre os teores de ácido ascórbico e carboidratos solúveis de morango (Fragaria hybridus)

Several growth regulators were sprayed on strawberry plants: SADH (5000 ppm), CCC (2000 ppm), IAA (10 ppm, 3 times), GA 10 ppm, 3 times) and GA (550 ppm), Ascorbic acid, dry weight and soluble carbohydrates contents of fruits were determined. Statistically differences were not observed between treatments and control. Dry weight varied from 7.62 to 9.53%. Ascorbic acid content varied from 35.88 to 71.81 mg/100 g on fresh weight basis. Mean values of soluble carbohydrates, in grams/100 g on fresh weight basis, were total (5.58), sucrose (1.01), glucose (1.63) and frutose (1.54).Foram feitas aplicações dos seguintes reguladores de crescimento em morango (Fragarm hybridus): SADH a 5000 ppm, CCC a 2000 ppm, ATA a 10 ppm (3 aplicações), ácido giberélico a 10 ppm (3 aplicações) e 550 ppm. Análises de peso seco, ácido ascórbico e carboidratos solúveis dos frutos foram efetuadas a fim de se estudar o efeito desses reguladores de crescimento. Não foram detectadas diferenças significativas entre os diversas tratamentos e o controle. O peso seco variou de 7,62 a 9,53%. O conteúdo de ácido ascórbico variou de 35,88 a 71,81 mg/100 g de peso fresco. Os teores médios de carboidratos solúveis, expresso em g/100 g peso fresco, foram: totais (5,58), sacarose (1,01), glucose (1,63) e frutose (1,54)

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations

Purpose To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. Patients and Methods One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara-C [DA]) induction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO). The primary end point was overall survival (OS). Results There was no difference in remission rate after two courses between FLAG-Ida + GO and DA + GO (complete remission [CR] + CR with incomplete hematologic recovery 93% v 91%) or in day 60 mortality (4.3% v 4.6%). There was no difference in OS (66% v 63%; P = .41); however, the risk of relapse was lower with FLAG-Ida + GO (24% v 41%; P < .001) and 3-year event-free survival was higher (57% v 45%; P < .001). In patients with an NPM1 mutation (30%), 3-year OS was significantly higher with FLAG-Ida + GO (82% v 64%; P = .005). NPM1 measurable residual disease (MRD) clearance was also greater, with 88% versus 77% becoming MRD-negative in peripheral blood after cycle 2 (P = .02). Three-year OS was also higher in patients with a FLT3 mutation (64% v 54%; P = .047). Fewer transplants were performed in patients receiving FLAG-Ida + GO (238 v 278; P = .02). There was no difference in outcome according to the number of GO doses, although NPM1 MRD clearance was higher with two doses in the DA arm. Patients with core binding factor AML treated with DA and one dose of GO had a 3-year OS of 96% with no survival benefit from FLAG-Ida + GO. Conclusion Overall, FLAG-Ida + GO significantly reduced relapse without improving OS. However, exploratory analyses show that patients with NPM1 and FLT3 mutations had substantial improvements in OS. By contrast, in patients with core binding factor AML, outcomes were excellent with DA + GO with no FLAG-Ida benefit

Ligand effects in selective carbonyl addition reactions of organomanganese and cerium reagents

Transmetalation of organolithium reagents RLi (R = CH3, n-Bu) with manganese pivalate produces reagents of the type RMnOC(O)tBu which react stereoselectively with substituted cyclohexanones to afford the axial alcohols preferentially. These reagents as well as cerium ate complexes RCe(OiPr)3MgX react aldehyde-selectively in the presence of ketone functionalit

Cram Selectivity in the Reaction of 2-Phenylpropanal with Alkyllithium Reagents: Myth and Reality

The reaction of racemic 2-phenylpropanal with methyl- and n-butyllithium was studied in detail. Factors such as temperature, solvent, rate of addition, presence of salts, scale-up and source of reagents were carefully examined. Cram-selectivities of 90 –94% were routinely reached under standard conditions (THF, −78°C), which is significantly higher than previously reported for these classical reaction

Cloning of PCP1, a member of a family of pollen coat protein (PCP) genes from Brassica oleracea encoding novel cysteine-rich proteins involved in pollen-stigma interactions.

The pollen coatings of both Brassica oleracea and Brassica napus contain a small family of basic 6-8 kDa proteins which are released on to the stigmatic surface on pollination. Following partial amino-acid sequencing of one of these pollen coat proteins (PCPs), PCR primers were constructed to isolate the PCP sequence from anther mRNA using RT-PCR. A cDNA was obtained which, in Northern hybridization experiments, revealed a characteristic pattern of expression during late stages of anther development. Interestingly, in situ hybridization revealed expression of this sequence to be confined to the cytoplasm of the trinucleate pollen grains: no signal was detected in the tapetum. Southern hybridization experiments have shown the gene (PCP1) to be a member of a large family of between 30 and 40 PCP genes in the genome of Brassica oleracea. Surprisingly, RFLP experiments showed reduced copy number (one to two copies) in some of the F2 segregants, perhaps resulting from the clustering of PCP sequences. PCP1 contains a single intron and encodes a small, basic peptide 83 amino acids in length featuring a hydrophobic signal peptide sequence separated from the more hydrophilic, cysteine-rich mature protein. The central part and C-terminal region of the peptide contain a characteristic and invariant pattern of eight cysteines which show clear homology with a number of other anther-specific genes; the remainder of the sequence shows little similarity to other sequences on the data bases. The product of PCP1 is a member of a large family of similar proteins, some of which have been demonstrated to bind specifically to S-locus glycoproteins, but does not appear to be genetically linked to the S-locus